Skip to main content
. Author manuscript; available in PMC: 2010 May 1.
Published in final edited form as: IUBMB Life. 2009 May;61(5):528–536. doi: 10.1002/iub.180

Figure 2. Scheme summarizing the genomic and non-genomic actions of a TRβ mutant in tumorigenesis.

Figure 2

The TRβPV mutant interferes with the transcriptional activity of wild-type TRs, thereby altering the transcriptional activity of the tumor suppressor PPARγ in the thyroid (29,31) and activating cyclin D1 expression in the pituitary (27). TRβPV also exerts its oncogenic actions in the thyroid by acting through non-genomic mechanisms involving protein-protein interaction, thereby leading to PI3K-AKT overactivation (32) and accumulation of PTTG (33) and β-catenin proteins (34) (see text for detailed explanations).